about
Renal tumors: diagnostic and prognostic biomarkersDetection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCREmphasizing the role of Wnt5a protein expression to predict favorable outcome after radical prostatectomy in patients with low-grade prostate cancerProteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model.Messenger ribonucleic acid levels of steroid 5 alpha-reductase 2 in human prostate predict the enzyme activity.Evaluation of two sample preparation methods for prostate proteome analysis.Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer.Tumor specific phage particles promote tumor regression in a mouse melanoma model.Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4Distribution of prostasomes in neoplastic epithelial prostate cells.Pathology in prostate research: optimizing the pathological data.Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcomeIdentification of new differentially methylated genes that have potential functional consequences in prostate cancer.Phospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expressionSwitch to full-length of XAF1 mRNA expression in prostate cancer cells by the DNA methylation inhibitor.Standardization of Gleason grading among 337 European pathologists.TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers.Gene expression profiling identifies clinically relevant subtypes of prostate cancer.Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives.Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists.A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.Current status of prognostic immunohistochemical markers for urothelial bladder cancer.International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins.International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens: rationale and organization.International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease.International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume.International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes.International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling.Proteomics in clinical prostate research.Pathology in prostate research: optimizing tissue quality.Role of histopathology and molecular markers in the active surveillance of prostate cancer.Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers.International society of urological pathology consensus conference on handling and staging of radical prostatectomy specimens.Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading.Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens.Handling of radical prostatectomy specimens.A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens.Implications of the International Society of Urological Pathology modified Gleason grading system.Contemporary grading for prostate cancer: implications for patient care.
P50
Q26860500-926F3930-DC2D-43AA-B0B2-EC4A1937B771Q28209605-941D47BB-691F-4013-BDA0-8E76A0B735D3Q28709995-1576F276-4AD3-491B-815C-7EEAD3EC2F93Q30816988-88A992B0-9A01-44B0-BC0A-A58E07ECE7BCQ31831614-8C9C4791-D13C-485D-B726-CED328EEB45BQ33246459-D1E677E8-51D9-4DD6-9DC3-2EC8727A2819Q33252846-A4DBFE75-0104-4574-9CFD-F1400B5F3E71Q33257201-E16E1A88-F808-4CC9-8534-3FBAA3781B99Q33680523-FAEF9E7F-984B-48FE-B084-BA892A221529Q33860130-5AAB0392-1437-4891-92DE-DB0D86BFF03BQ33909029-49C57F55-1931-4947-8077-DA90B3E6EE54Q34028208-8B2E10E5-3628-4E73-94E9-934B7A2BE5DEQ34465132-8C111167-142D-471E-BA00-A3A029E97E6FQ34469245-DAB01817-3299-4363-83C5-345003C0725BQ34476189-D2969379-F593-4FC1-9111-2E9BA705BE2DQ34512822-C0760C7D-04E3-45AA-A979-6C75A15C8C73Q35088099-4BAACB55-C8CC-4ADA-8254-13EFC8613E0EQ35554359-855FE27C-D481-4062-81A0-31D0C2351614Q35723957-215A8196-735E-455D-BECF-DD6488B3E8FFQ36194948-B1157FCF-9158-4818-973D-F4BBFDB5AE2BQ36388831-905CAABD-6276-4DFA-84D4-234E226F5F33Q36626087-505FBD1D-F300-4E69-9309-0289DAB989D2Q37317797-C5DC2C2D-A0A5-4C7F-AB6F-3EA594763114Q37781683-D36009ED-D642-4CB2-8B7D-4476BCDC7E16Q37783903-B861211B-3E24-4470-A2F4-2048309D0F8EQ37783904-9FCE6679-E940-4D7B-8547-D5F785CB886AQ37785484-9A35E3F3-E850-481D-90E5-0CBFE8D2DD0FQ37785485-6BAE56C3-D3AA-491F-9903-27E8B55B69B7Q37787737-481DA9FB-4ACA-414F-A6A3-C908ED922B3CQ37817140-FFB92BA4-11DE-4CAE-8563-115D04120D83Q37878467-39E0B80C-1601-4E02-9DB6-4890EAAC643DQ37878468-F68A666A-FCFB-4743-B2C9-8D14A071F53EQ37878470-91F73831-727F-476E-901B-AF9C346341C4Q37886567-2A1320BE-CA75-49A6-B661-7210C8379EA6Q37893527-2B99DF87-DEA0-4AEA-A860-81DEBC71FFA3Q37895892-8E4E5A8D-A3EF-4971-8EEC-B50C03F81EE2Q37972701-B074A4D9-85E1-4555-9CB6-DEC33CD510E2Q37993973-6CA36445-DED5-484A-84E9-43594A54D187Q37998171-025097D0-EAF6-4E48-8763-D50CFD3D053AQ38054925-2E91FC22-45E5-49EB-B565-88D3355871C1
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Lars Egevad
@ast
Lars Egevad
@en
Lars Egevad
@es
Lars Egevad
@nl
Lars Egevad
@sl
type
label
Lars Egevad
@ast
Lars Egevad
@en
Lars Egevad
@es
Lars Egevad
@nl
Lars Egevad
@sl
prefLabel
Lars Egevad
@ast
Lars Egevad
@en
Lars Egevad
@es
Lars Egevad
@nl
Lars Egevad
@sl
P106
P21
P31
P496
0000-0001-8531-222X